Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) is attracting investor attention: Here is what you should know
CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...
Researchers developed a CRISPR-based system that spreads through bacterial populations to disable antibiotic resistance genes ...
One of the most well-known versions of the gene-editing tool CRISPR may not work in a large proportion of the population, according to recent research out of Stanford University in California. CRISPR, ...
Add Yahoo as a preferred source to see more of our stories on Google. Stanford researchers have developed CRISPR-GPT, an AI-powered copilot that guides gene-editing experiments. (CREDIT: Shutterstock) ...
Scientists in China report removing HIV from human DNA using gene-editing technology. Experts say the findings are promising but still far from a confirmed cure.
A new light-based sensor can spot incredibly tiny amounts of cancer biomarkers in blood, raising the possibility of earlier ...
VedaBio, a pioneering biotechnology company transforming molecular detection, today announced a non-exclusive license agreement with Mammoth Biosciences, Inc. for the use of select CRISPR-based ...
In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...
A novel CRISPR-based technology can spread within bacterial populations to eliminate antibiotic resistance.
CRISPR biosensors are transforming healthcare by detecting biomarkers at attomolar sensitivity, enabling real-time health monitoring through wearable patches and implantable sensors. They continuously ...
Researchers have developed a technology that delivers RNA to damaged neurons and stimulates regrowth - paving the way for potential treatments for neurodegenerative diseases like ALS and spinal ...
With this in mind, let's check out a blastoff-ready biotech stock you'll kick yourself for not buying in 2026. Image source: Getty Images.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results